Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH)

0.4299
Delayed Data
As of Mar 29
 -0.0039 / -0.90%
Today’s Change
0.38
Today|||52-Week Range
4.40
-33.77%
Year-to-Date
Cara Therapeutics (CARA) Shows Strength: Stock Up 5.2%
Mar 29 / Zacks.com - Paid Partner Content
AveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher
Mar 20 / Zacks.com - Paid Partner Content
Will Endo's Troubles Continue to Dent Performance in 2017?
Mar 28 / Zacks.com - Paid Partner Content
Valeant (VRX) Shares up on ValueAct's 5.2% Stake Increase
Mar 17 / Zacks.com - Paid Partner Content
AstraZeneca's Lung Cancer Drug Tagrisso Approved in China
Mar 27 / Zacks.com - Paid Partner Content
Implied Volatility Surging for Anthera (ANTH) Stock Options
Mar 17 / Zacks.com - Paid Partner Content
Merrimack (MACK) Starts Enrollment in Solid Tumors Study
Mar 24 / Zacks.com - Paid Partner Content
Shire's (SHPG) Cinryze Label Expanded for Pediatric Use
Mar 16 / Zacks.com - Paid Partner Content
Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
Mar 23 / Zacks.com - Paid Partner Content
Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA
Mar 16 / Zacks.com - Paid Partner Content
OvaScience, Inc. (OVAS) Looks Good: Stock Up 9.6% Higher
Mar 23 / Zacks.com - Paid Partner Content
Inovio (INO) Q4 Loss Wider than Expected; Shares Decline
Mar 16 / Zacks.com - Paid Partner Content
Enzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2%
Mar 21 / Zacks.com - Paid Partner Content
Rexahn Pharmaceuticals (RNN) Jumps: Stock Moves Up 5.4%
Mar 16 / Zacks.com - Paid Partner Content
Fortress Biotech (FBIO) Catches Eye: Stock Moves Up 8.3%
Mar 20 / Zacks.com - Paid Partner Content